KRAS and neoplasm: Qiong J Wang isolated one T cell receptor with high affinity for the mutated KRAS variants G12V and G12D, transduced peripheral blood lymphocytes (PBLs) with these TCRs and found that these genetically engineered PBLs could recognize multiple HLA-A*11:01+ tumor lines that destroy these target cells; in addition, the adoptive transfer of these transduced PBLs could significantly reduce the growth of tumors in a xenograft model (66).